Previous Article | Next Article 
Journal of Clinical Microbiology, September 1999, p. 2904-2909, Vol. 37, No. 9
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
International Multicenter Evaluation of the
Clinical Utility of a Dipstick Assay for Detection of
Leptospira-Specific Immunoglobulin M Antibodies in Human
Serum Specimens
Henk L.
Smits,1,*
Yulia V.
Ananyina,2
Annette
Chereshsky,3
Louella
Dancel,4
Rudy F. M.
Lai-A-Fat,
Howard D.
Chee,6
Paul N.
Levett,7
Toshiyuki
Masuzawa,8
Yasutake
Yanagihara,8
M. A.
Muthusethupathi,9
Eduard J.
Sanders,10,11
David M.
Sasaki,12
Harry
Domen,13
Claude
Yersin,14
Tin
Aye,15
Sandra L.
Bragg,15
George C.
Gussenhoven,1
Marga G. A.
Goris,1
Wiepko J.
Terpstra,1 and
Rudy A.
Hartskeerl1
Department for Biomedical Research, Royal
Tropical Institute, Amsterdam, The Netherlands1;
Gamaleya Research Institute for Epidemiology and Microbiology,
Russian Academy of Medical Science, Moscow,
Russia2; ESR: Health Communicable
Disease Centre, Wellington, New Zealand3;
Department of Medical Microbiology, College of Public Health,
University of Philippines Manila, Manila,
Philippines4; Department of Dermatology
and Department of Internal Medicine,6
Academic Hospital, Paramaribo, Surinam; Leptospira Laboratory,
Ministry of Health and the Environment, St. Michael,
Barbados7; Department of Microbiology,
School of Pharmaceutical Sciences, dUniversity of Shizuoka,
Shizuoka, Japan8; Department of
Nephrology, Chennai Medical College of Tamil Nadu, Chennai,
India9; Dengue Branch, Division of
Vector-Born Infectious Diseases, Centers for Disease Control and
Prevention, San Juan, Puerto Rico10;
Epidemiology Program Office11 and
Meningitis and Special Pathogens Branch, Division of Bacterial
and Mycotic Diseases,15 Centers for Disease
Control and Prevention, Atlanta, Georgia; Epidemiology
Branch, Department of Health, Hawaii, Department of Health,
Honolulu, Hawaii12; Medical
Microbiology Branch, Department of Health, Pearl City,
Hawaii13; and Department of
Medicine, Victoria Hospital, Victoria, Seychelles14
Received 20 January 1999/Returned for modification 8 April
1999/Accepted 4 June 1999
 |
ABSTRACT |
We performed a multicenter evaluation of a robust and easily
performed dipstick assay for the serodiagnosis of human leptospirosis. The assay is aimed at the detection of Leptospira-specific
immunoglobulin M (IgM) antibodies. The study involved 2,665 serum
samples collected from 2,057 patients with suspected leptospirosis in
12 countries on five continents with different levels of endemicity and
different surveillance systems. The patients were grouped as
laboratory-confirmed leptospirosis case patients and noncase patients
based on the results of culturing and the microscopic agglutination
test. Paired samples from 27.7% of the subjects were tested. Of the
485 case patients, 87.4% had a positive dipstick result for one or
more samples. Of the 1,513 noncase patients, only 7.2% had a positive result. Whereas most (88.4%) of the positive samples from the case
patients showed moderate to strong (2+ to 4+) staining in the dipstick
assay, most (68.1%) of the positive samples from the noncase patients
showed weak (1+) staining. The sensitivity of the dipstick assay
increased from 60.1% for acute-phase serum samples to 87.4% for
convalescent-phase samples. The specificities for these two groups of
samples were 94.1 and 92.7%, respectively. The dipstick assay detected
a broad variety of serogroups. The results of the dipstick assay were
concordant (observed agreement, 93.2%; kappa value, 0.76) with the
results of an enzyme-linked immunosorbent assay for the detection of
specific IgM antibodies, a test which is often used in the laboratory
diagnosis of current or recent leptospirosis. This study demonstrated
that this easily performed dipstick assay is a valuable and useful test
for the quick screening for leptospirosis; has a wide applicability in different countries with different degrees of endemicity; can be used
at all levels of the health care system, including the field; and will
be useful for detecting and monitoring outbreaks of leptospirosis.
 |
INTRODUCTION |
Leptospirosis is a worldwide
zoonosis caused by pathogenic spirochetes of the genus
Leptospira (2, 4). Leptospirosis is a fairly
common disease in humid and warm climates (1, 3). The
disease varies from a mild flu-like form to severe forms, such as
Weil's syndrome, which are characterized by renal failure, liver
impairments, and hemorrhages and have a high mortality rate. Due to the
complexity of the clinical symptoms and signs, leptospirosis is often
misdiagnosed. Thus, laboratory support of the clinical diagnosis is
essential (10).
Laboratory confirmation of leptospirosis is obtained when either the
pathogen is isolated or a positive serological result is obtained. The
microscopic agglutination test (MAT) is considered the reference test
for leptospirosis. The result of the MAT is considered consistent with
leptospirosis when either a
4-fold increase in titer is observed
between paired serum samples or a significantly increased titer is
observed for a single serum sample (13). Recently, we
developed a quick and easily performed dipstick assay, the LEPTO
dipstick (5), for the serodiagnosis of leptospirosis. This
assay, like the immunoglobulin M (IgM) enzyme-linked immunosorbent
assay (ELISA) (11, 12), detects Leptospira-specific IgM antibodies in human sera and is
aimed at the serodiagnosis of current or recent leptospirosis. The test needs no special equipment, and its ingredients are highly stable and
do not need refrigeration.
A previous evaluation of the dipstick assay with selected serum samples
collected mainly in The Netherlands demonstrated high sensitivity and
specificity and showed that the results correlated well with those of
the ELISA (5). We argued that the dipstick assay could be a
useful diagnostic tool for health facilities with few resources and in
countries with different levels of endemicity. The detection of
specific IgM antibodies could be useful in particular in countries with
a high degree of endemicity to help distinguish between acute or recent
leptospirosis and past leptospirosis. The present study was conducted
to evaluate the performance of the dipstick assay in different
countries, including countries with low and countries with high
prevalences of the disease. In this study, the performance of the
dipstick assay was evaluated with serum samples from patients with
suspected leptospiral infection and grouped as laboratory-confirmed
leptospirosis case patients or noncase patients based on the results of
culturing and the MAT. The results of the dipstick assay also were
compared with those of the IgM ELISA.
 |
MATERIALS AND METHODS |
Participating laboratories and study groups.
Serum samples
collected during a certain period from all patients with a clinical
suspicion of leptospirosis at nine laboratories in Barbados, Hawaii,
India, New Zealand, the Philippines, Russia, the Seychelles, Surinam,
and The Netherlands were included in the study. In Surinam, samples
were collected during two different periods (studies I and II). In
addition, the dipstick assay was tested with samples collected from
patients with fever in rural hospitals in Kenya and Thailand. In Puerto
Rico, the dipstick assay was tested with samples collected from
patients who had a dengue-like illness, who failed to demonstrate
anti-dengue virus IgM antibodies (6, 7), and who were thus
considered negative for dengue.
Leptospirosis case definition and composition of study
groups.
Patients with a clinical suspicion of leptospirosis were
grouped as laboratory-confirmed leptospirosis case patients and noncase patients based on the results of laboratory procedures (culturing and
MAT) performed and interpreted according to criteria routinely used in
each of the laboratories performing the tests (Table
1). Paired serum samples were available
from 27.7% of the patients, so confirmation of leptospirosis by
demonstration of seroconversion or a
4-fold rise in the MAT titer was
possible for only a portion of the patients. Hence, a single raised MAT
titer was accepted as the confirmation of leptospirosis for single
serum samples (13). Patients in the study groups from Hawaii
and the Seychelles and with MAT titers above the cutoff value but not
showing seroconversion or a
4-fold rise in titer were considered
probable leptospirosis patients. These patients were excluded from the
analysis. The numbers of case patients and noncase patients, the number
of serum samples for each of these groups, and the percentage of
patients with more than one sample are shown in Table
2.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Composition of study groups and number and percentage of
patients with a positive result in the dipstick assay
|
|
The MAT was performed at the Royal Tropical Institute, Amsterdam, The
Netherlands, for the study groups from The Netherlands, Surinam,
Thailand, and Kenya. The MAT was performed in New Caledonia for samples
from the Seychelles, in Japan for samples from the Philippines, and in
the United States for samples from Puerto Rico and Hawaii (Table 1).
For all other study groups, the MAT was performed at the collaborating
laboratories contributing the samples. A detailed description of the
panels of strains used in the MAT and the experimental procedures used
for performing the MAT can be obtained from the authors.
The IgM ELISA was performed for seven of the study groups. The results
of the IgM ELISA, although often used in the serodiagnosis of
leptospirosis, were not taken into consideration for the definition of
leptospirosis case patients, as doing so would cause bias for the
presence of specific IgM antibodies.
LEPTO dipstick assay.
Participants in the study were
provided with sealed vials containing (i) 5 ml of lyophilized detection
reagent, (ii) 5 ml of reconstitution fluid, and (iii) 5 ml of dipstick
fluid; a tightly closed container containing dipsticks and a desiccant;
test tubes; and a test tube rack. Participants were asked to perform
the test according to the instructions given in an accompanying
protocol (5). Briefly, the dipstick assay is performed by
incubation of a wet dipstick in a mixture of 250 µl of reconstituted
detection reagent and 5 µl of serum at an ambient temperature for
3 h. At the end of the incubation period, the dipstick is rinsed
with tap water and air dried, and the staining intensity of the antigen band is compared with that of a colored reference strip showing bands
colored at different (1+ to 4+) intensities. In the evaluation of the
dipstick assay, a staining intensity of
+1 is considered positive.
Dipsticks are coated with a heat-stable antigen prepared from a culture
of Leptospira biflexa.
ELISA.
An ELISA for the detection of
Leptospira-specific IgM antibodies (IgM ELISA) was performed
at the Department for Biomedical Research of the Royal Tropical
Institute with the serum samples from The Netherlands, Thailand, Puerto
Rico, Hawaii, Surinam (study II), and the Seychelles. The ELISA was
performed with antigen prepared from strain Wijnberg as described
elsewhere (11, 12). The results of the ELISA were considered
positive when a titer of
1:40 was obtained. For the Barbados samples,
the ELISA was performed with antigen prepared from strain Patoc I as
described previously (8).
Statistical evaluation.
To calculate the sensitivity and
specificity of the dipstick assay, the serum samples from leptospirosis
case patients and noncase patients were stratified in stage I and stage
II. For patients with paired samples, the samples collected first were considered stage I and the samples collected second were considered stage II. For patients from whom more than two samples were obtained, only the first two samples were considered. Single samples were considered stage I when collected during the first 10 days of the
disease and stage II when collected more than 10 days after the onset
of the disease, as IgM antibodies usually develop during the first 10 days of the disease (2). Single samples for which the
duration of the disease was not reported were excluded from the
analysis. Also, samples from patients with reported past leptospirosis were excluded from the analysis.
To compare the performance of the dipstick assay with that of the IgM
ELISA, the intermethod agreement between the results of the two tests
was determined. Kappa statistics were applied, as they offer a measure
of agreement which is not attributable to chance. In general, a kappa
value of >0.80 represents almost perfect agreement beyond chance.
Values below 0.40 represent slight agreement, and values between 0.40 and 0.80 represent fair to good agreement.
 |
RESULTS |
Study population.
In 12 countries on five continents, 2,665 serum samples from 2,057 patients with a clinical suspicion of
leptospirosis were tested with the dipstick assay. According to the
results of the MAT and culturing, 485 patients with 729 samples were
considered leptospirosis case patients, 1,513 patients with 1,841 samples were considered noncase patients, and 59 patients with 95 samples were considered patients with probable leptospirosis. Paired
samples were tested from 27.7% of the patients, including 217 case
patients and 317 noncase patients (Table 2).
Percentage of leptospirosis case patients and noncase patients with
a positive dipstick assay result.
The mean percentage of case
patients with one or more serum samples that showed staining of the
antigen band of the dipstick was 87.4%; the percentages ranged from
76.5 to 88.2% for five studies and to over 90% for seven other
studies (Table 2). For the studies performed in India, the Seychelles,
and Thailand, the percentages of case patients with a positive dipstick
result were relatively low, namely, 77.8, 78.7, and 76.5%,
respectively. The samples from two of the four case patients in the
study group from Thailand with negative results in the dipstick test
showed borderline titers in the MAT. These samples also were negative in the IgM ELISA. The samples from 13 of the 17 case patients from the
Seychelles with negative dipstick test results showed seroconversion in
the MAT to a titer at or just above the cutoff value. The samples from
12 of these 13 case patients also were negative in the IgM ELISA. The
agglutinating titers were not specified for the study performed in
India. Also, an ELISA was not performed on the samples from India.
Samples from 7.2% (on average) of the noncase patients tested positive
in the dipstick assay. The percentage of noncase patients with a
positive score in the dipstick assay ranged from 0.6 to 20% for the
different study groups (Table 2).
The percentage of probable leptospirosis patients from Hawaii and the
Seychelles that tested positive in the dipstick assay did not differ
from the percentage of case patients that tested positive.
Staining intensity of the antigen band.
Semiquantitation of
the dipstick results was used for all study groups, with the exception
of some of the samples from Hawaii. The staining intensity of the
antigen band on the dipstick was moderate to strong (
2+) for most
(88.4%) of the samples from the case patients with a positive score
(Table 3). In contrast to the findings
for the other study groups, a large proportion of the sera from the
case patients in the Philippines stained weakly (1+) (data not shown).
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Staining intensity of positive serum samples and
stratification according to the duration of the disease
|
|
As expected, a higher percentage of the stage II serum samples from the
case patients showed staining, and the staining intensity was, on
average, stronger than that of stage I serum samples (Table 3).
Analysis of the results for study groups for which the time point of
sample collection in relation to the duration of the disease was well
documented (Barbados, The Netherlands, the Seychelles, and Hawaii)
indicated that the majority of the positive samples showed moderate to
strong staining intensity by day 6 or 7 after the onset of the disease
(data not shown).
The staining intensity for 68.1% of the samples from the noncase
patients with a positive result in the dipstick assay was rated 1+
(Table 3). Staining intensities of
2+ for samples from the noncase
patients were notably found in the study groups from New Zealand and
Surinam (study I).
Sensitivity and specificity of the dipstick assay.
The mean
sensitivity of the dipstick assay for stage I serum samples was
calculated to be 60.1% (standard deviation [SD], 17.0) and ranged
from just over 35% for the samples studied in the Seychelles,
Thailand, and New Zealand to about 80% for the samples studied in
Barbados, India, and Puerto Rico (Table
4). The mean sensitivity for stage II
samples was 87.4% (SD, 10.9) and ranged from 69.2% for the samples
studied in India to over 95% for the samples studied in Barbados, New
Zealand, Puerto Rico, Russia, and The Netherlands.
View this table:
[in this window]
[in a new window]
|
TABLE 4.
Sensitivity and specificity of the LEPTO dipstick assay
in the acute phase of disease for groups of serum samples stratified
according to the duration of the disease
|
|
The mean specificities of the dipstick assay for stage I and stage II
samples were calculated to be 94.1% (SD, 4.4) and 92.7% (SD, 5.8),
respectively (Table 4).
The sensitivity and specificity for the study groups for which
information on the duration of the disease was lacking are presented in
Table 5. The mean sensitivity was 91.6%
(SD, 2.5), and the mean specificity was 88.6% (SD, 7.0).
View this table:
[in this window]
[in a new window]
|
TABLE 5.
Sensitivity and specificity of the LEPTO dipstick assay
in the acute phase of disease for groups of serum samples for which the
exact duration of the disease was not reported
|
|
Comparison of the dipstick assay and the IgM ELISA.
The IgM
ELISA was performed for the samples from Barbados, Hawaii, The
Netherlands, Puerto Rico, Surinam (study II), the Seychelles, and
Thailand. A comparison of the test results of the dipstick assay and
the IgM ELISA yielded kappa values (agreement beyond chance) ranging
from 0.69 for the group of samples from Puerto Rico to 0.83 for the
group of samples from the Seychelles (Table 6). The mean observed agreement was
93.2%, and the mean kappa value was 0.76. These results show that the
dipstick assay and the IgM ELISA yield concordant results. Discrepant
results were obtained mainly for sera either with a borderline titer in
the ELISA or showing weak staining in the dipstick assay.
 |
DISCUSSION |
The present study was initiated to evaluate the clinical utility
of a dipstick assay for the detection of Leptospira-specific IgM antibodies in different areas likely to have different degrees of
endemicity and where strains of different serovars cause leptospirosis. The results show that the dipstick assay combines a high specificity with a high sensitivity, in particular for samples collected in the
convalescent phase of the disease. The mean sensitivity increased from
60.1% (SD, 17.0) for samples collected early in the acute phase of the
disease to 87.4% (SD, 10.9) for samples collected later in the
disease. The mean specificities for these two groups of samples were
94.1% (SD, 4.4) and 92.7% (SD, 5.8), respectively. Furthermore, most
(88.4%) of the positive samples from the case patients gave a moderate
to strong (2+ to 4+) staining intensity, and most (68.1%) of the
positive samples from the noncase patients gave a weak (1+) staining
intensity only.
We previously evaluated the dipstick assay with selected serum samples
from leptospirosis case patients and noncase patients from The
Netherlands (5). In that study, a sensitivity of 63.0% for
acute-phase serum samples, a sensitivity of 85.7% for
convalescent-phase serum samples, and a specificity of 92.7% were
calculated. The present multicenter study included samples collected
prospectively in The Netherlands and sent to the Royal Tropical
Institute in 1996 because of a suspicion of leptospirosis or because
leptospirosis was in the differential diagnosis. The results of both
studies show good agreement. In the present study, a higher sensitivity (95.2%) was observed for convalescent-phase samples, the sensitivity (60.1%) for acute-phase samples was similar, and the specificity was
slightly higher.
The incidence of leptospirosis is relatively low in The Netherlands. In
the present study, we demonstrated that the dipstick assay can be
applied successfully in different parts of the world, including areas
with a high endemicity of leptospirosis. The variation in test
performance noted for the different study groups likely is attributable
to differences in the interpretation of the results of the reference
test (MAT) by the different centers involved in the study. Differences
in clinical practices and in the collection of clinical data may have
contributed to some variation as well. Differences in methodology
presumably had a stronger effect on the results of the dipstick assay
than did possible epidemiological differences. Differences in the
sensitivity calculated for the dipstick assay for samples collected in
the acute phase of the disease most likely were due to differences in
the accuracy of the reported duration of the disease at the time of
sampling. For instance, the relatively high sensitivity calculated for
the acute-phase samples in the study performed in India could have been
caused by the fact that the patients in this study group first sought
medical attention at a late stage of the disease and underreported the
duration of the disease. Also, the high sensitivity calculated for the
study groups in the Philippines and Surinam (Table 5) suggested that
the samples from these groups were collected at a relatively late stage
of the disease. The relatively low sensitivity observed for the
convalescent-phase samples from the study groups in Hawaii, India, the
Seychelles, and Thailand could have been a result of false-positive
results obtained in the reference test. The majority of the case
patients with serum samples for which a negative result was observed in the dipstick assay had low or borderline titers in the MAT as well as
borderline or negative results in the IgM ELISA. The absence of
detectable Leptospira-specific IgM levels in these patients suggests that the final diagnosis of laboratory-confirmed leptospirosis could be disputed for these patients. It is possible that some of these
patients had residual antibody levels agglutinating in the MAT from a
previous Leptospira infection.
We previously demonstrated that the dipstick assay reacted equally well
with sera from patients infected with strains of the serogroups
Australis, Autumnalis, Icterohaemorrhagiae, Grippothyphosa, Sejroe, and
Pomona (5). In the present study, reactivity with a total of
22 serogroups was demonstrated (data not shown). The lack of reactivity
with sera from some case patients was not related to agglutination by
strains belonging to a specific serogroup. The results of this
multicenter study indicate that the dipstick assay has a broad
reactivity and is widely applicable. As the dipstick assay yields
results quickly and is simple to perform and the assay components are
highly stable and do not need refrigeration, the test in particular may
fulfill needs in situations where facilities or resources needed to
perform more complicated standard laboratory tests such as the MAT or
the ELISA are lacking. The observed high degree of concordance between
the results of the dipstick assay and the ELISA (mean observed
agreement, 93.2%; kappa value, 0.76) shows that similar results will
be obtained when either of the tests is used. The sensitivity of the
IgM ELISA is lower than that of the dipstick assay for acute-phase
samples but is slightly higher for convalescent-phase samples
(5). The specificity of the IgM ELISA is higher
(5). Assays aimed at the detection of
Leptospira-specific IgM antibodies have somewhat lower
sensitivity and specificity than the MAT. In our study, serum samples
from about 10% of the case patients did not react in the dipstick
assay, and samples from about 9% of the noncase patients showed weak to moderate staining. Although it is possible that some of the patients
were misdiagnosed by the reference test, one should consider the
possibility of false-positive and false-negative results when applying
the dipstick assay.
When the dipstick assay is used as a screening test, a high negative
predictive value is important. The predictive value of a test varies
with the prevalence of the disease in the target population. The
prevalence of leptospirosis among patients with a clinical suspicion of
leptospirosis in the study group tested in The Netherlands was 4.1%.
The negative predictive value for this study group was 98.0% (95%
confidence interval, 96 to 99). From the results of Table 3 it can be
calculated that a mean prevalence of leptospirosis of 29.5% among
patients with a clinical suspicion of leptospirosis, the negative
predictive value would be 90.8% (95% confidence interval, 89 to 92).
The dipstick assay primarily has been developed as a rapid screening
assay. It is envisaged that due to a lack of facilities or resources
needed to perform more complicated confirmatory tests, the dipstick
assay may be used as a diagnostic assay. A high positive predictive value will be important for use of the dipstick assay as a diagnostic test. As the majority of the dipstick assay positive results obtained for the noncase patients showed weak (1+) staining, the positive predictive value was calculated separately for results with a weak
staining intensity and for results with a moderate to strong (
2+)
staining intensity. For a test result with a moderate to strong
staining intensity, a positive predictive value of 91.2% (95%
confidence interval, 75 to 98) was calculated for the study performed
in The Netherlands. The positive predictive value at a prevalence of
29.5% would be 93.8% (95% confidence interval, 91 to 96). The
positive predictive value for a test result with a weak staining
intensity was 47.1%.
The results of the dipstick assay, like the results of the MAT and the
ELISA, should be interpreted with respect to clinical findings. The
results obtained in this study show that a test result with a moderate
to strong staining intensity is highly consistent with leptospirosis.
Seroconversion usually takes place 6 to 7 days after the onset of the
disease, and a negative result or a result with a weak staining
intensity may be obtained when samples are collected early in the
disease. The present study shows that a moderate to strong reaction in
the dipstick assay is obtained by day 6 or 7 for most case patients
(data not shown). Demonstration of seroconversion provides strong
evidence of leptospirosis. Therefore, it is advised that the assay be
repeated with a sample collected a few days later when a negative
result is obtained for a sample collected early in the disease and when
the suspicion of leptospirosis remains.
The use of the dipstick assay may well lead to improved diagnosis and
treatment of patients with leptospirosis and to better knowledge and
understanding of the prevalence and epidemiology of the disease. As the
dipstick assay is genus specific, it does not provide information
regarding the serovar involved in the infection. Knowledge of the
serovar is not essential for treatment, but it might be important for
identifying possible sources of infection and for developing control
programs. Application of culturing and/or the MAT will be required to
obtain this information.
The dipstick assay may be universally applicable as a quick screening
test for leptospirosis. During this study, the value of the dipstick
test was demonstrated by showing a high proportion of strongly positive
serum samples among samples from patients with a clinical suspicion of
leptospirosis but for whom the resources to perform a reference test
were not locally available. Furthermore, the dipstick assay clearly
demonstrated the presence of leptospirosis among patients for whom the
disease was not considered, as was the case for the group of
dengue-negative patients from Puerto Rico. In the study performed in
Kenya, the dipstick assay excluded leptospirosis for patients with
pyrexia of unknown origin but proven to suffer from several infectious
diseases at a later stage.
 |
ACKNOWLEDGMENTS |
We thank P. Perolat, P. Bovet, P. Confait, C. N. Edwards, C. Whittington, S. Branch, G. Watt, S. Sumani, V. Ranga Rao, A. Dekker,
M. A. G. van der Hoorn, J. de Meza Brewster, H. van der Kemp,
B. J. van den Born, I. Gomez, and V. Vorndam for their valuable contributions. We also thank the staff of the Mumias Medical Hospital, Mumias, Kenya, for their contribution to this work. The secretarial assistance of I. M. Struiksma is greatly appreciated.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biomedical Research, Royal Tropical Institute, Meibergdreef 39, 1105 AZ
Amsterdam, The Netherlands. Phone: 31-20-5665470. Fax: 31-20-6971841. E-mail: H.Smits{at}kit.nl.
 |
REFERENCES |
| 1.
|
Alexander, A. D.
1980.
Leptospira, p. 367-382.
In
E. H. Lennette, A. Barlows, W. J. Hausler, Jr., and J. P. Truant (ed.), Manual of clinical microbiology, 3rd ed. American Society for Microbiology, Washington, D.C.
|
| 2.
|
Faine, S.
1987.
Guidelines for the control of leptospirosis.
Bull. W. H. O.
67:1-171.
|
| 3.
|
Faine, S.
1994.
Leptospira and leptospirosis.
CRC Press, Inc., Boca Raton, Fla.
|
| 4.
|
Farr, R. W.
1995.
Leptospirosis.
Clin. Infect. Dis.
21:1-8[Medline].
|
| 5.
|
Gussenhoven, G. C.,
M. A. W. G. van der Hoorn,
M. G. A. Goris,
W. J. Terpstra,
R. A. Hartskeerl,
B. W. Mol,
C. W. van Ingen, and H. L. Smits.
1997.
LEPTO dipstick, a dipstick assay for the detection of Leptospira-specific immunoglobulin M antibodies in human sera.
J. Clin. Microbiol.
35:92-97[Abstract].
|
| 6.
|
Innis, B. L.,
A. Nisilak, and S. Nimmannitya.
1989.
An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate.
Am. J. Trop. Med. Hyg.
40:418-427.
|
| 7.
|
Kuno, G.,
I. Gómez, and D. J. Gubler.
1987.
Detecting artificial anti-dengue IgM immune complexes using an enzyme-linked immunosorbent assay.
Am. J. Trop. Med. Hyg.
63:3153-3159.
|
| 8.
|
Levett, P. N., and C. U. Whittington.
1998.
Evaluation of the indirect hemagglutination assay for diagnosis of acute leptospirosis.
J. Clin. Microbiol.
36:11-14[Abstract/Free Full Text].
|
| 9.
|
Mazzolini, J.,
G. Dorta de Mazzolini, and M. Mailloux.
1974.
Possibilité de diagnostic serologique des leptospires à l'aide d'un antigène unique.
Ned. Mal. Infect.
4:253.
|
| 10.
|
Palmer, M. F.
1988.
Laboratory diagnosis of leptospirosis.
Med. Lab. Sci.
45:174-178[Medline].
|
| 11.
|
Terpstra, W. J.,
G. S. Ligthart, and G. J. Schoone.
1980.
Serodiagnosis of human leptospirosis by enzyme-linked-immunosorbent-assay (ELISA).
Zentbl. Bakteriol. Mikrobiol. Hyg. Abt. 1 Orig. Reihe A
247:400-405.
|
| 12.
|
Terpstra, W. J.,
G. S. Ligthart, and G. J. Schoone.
1985.
ELISA for the detection of specific IgM and IgG in human leptospirosis.
J. Gen. Microbiol.
131:377-385[Medline].
|
| 13.
|
World Health Organization.
1998.
Communicable disease surveillance kit.
World Health Organization, Geneva, Switzerland.
|
Journal of Clinical Microbiology, September 1999, p. 2904-2909, Vol. 37, No. 9
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
McBride, A. J. A., Santos, B. L., Queiroz, A., Santos, A. C., Hartskeerl, R. A., Reis, M. G., Ko, A. I.
(2007). Evaluation of Four Whole-Cell Leptospira-Based Serological Tests for Diagnosis of Urban Leptospirosis. CVI
14: 1245-1248
[Abstract]
[Full Text]
-
Croda, J., Ramos, J. G. R., Matsunaga, J., Queiroz, A., Homma, A., Riley, L. W., Haake, D. A., Reis, M. G., Ko, A. I.
(2007). Leptospira Immunoglobulin-Like Proteins as a Serodiagnostic Marker for Acute Leptospirosis. J. Clin. Microbiol.
45: 1528-1534
[Abstract]
[Full Text]
-
Hull-Jackson, C., Glass, M. B., Ari, M. D., Bragg, S. L., Branch, S. L., Whittington, C. U., Edwards, C. N., Levett, P. N.
(2006). Evaluation of a commercial latex agglutination assay for serological diagnosis of leptospirosis.. J. Clin. Microbiol.
44: 1853-1855
[Abstract]
[Full Text]
-
Levett, P. N, Morey, R. E, Galloway, R. L, Turner, D. E, Steigerwalt, A. G, Mayer, L. W
(2005). Detection of pathogenic leptospires by real-time quantitative PCR. J Med Microbiol
54: 45-49
[Abstract]
[Full Text]
-
Yitzhaki, S., Barnea, A., Keysary, A., Zahavy, E.
(2004). New Approach for Serological Testing for Leptospirosis by Using Detection of Leptospira Agglutination by Flow Cytometry Light Scatter Analysis. J. Clin. Microbiol.
42: 1680-1685
[Abstract]
[Full Text]
-
Priya, C. G., Bhavani, K., Rathinam, S. R., Muthukkaruppan, V. R.
(2003). Identification and evaluation of LPS antigen for serodiagnosis of uveitis associated with leptospirosis. J Med Microbiol
52: 667-673
[Abstract]
[Full Text]
-
Bajani, M. D., Ashford, D. A., Bragg, S. L., Woods, C. W., Aye, T., Spiegel, R. A., Plikaytis, B. D., Perkins, B. A., Phelan, M., Levett, P. N., Weyant, R. S.
(2003). Evaluation of Four Commercially Available Rapid Serologic Tests for Diagnosis of Leptospirosis. J. Clin. Microbiol.
41: 803-809
[Abstract]
[Full Text]
-
WATT, G., JONGSAKUL, K., SUTTINONT, C.
(2003). POSSIBLE SCRUB TYPHUS COINFECTIONS IN THAI AGRICULTURAL WORKERS HOSPITALIZED WITH LEPTOSPIROSIS. Am J Trop Med Hyg
68: 89-91
[Abstract]
[Full Text]
-
Effler, P. V., Bogard, A. K., Domen, H. Y., Katz, A. R., Higa, H. Y., Sasaki, D. M.
(2002). Evaluation of Eight Rapid Screening Tests for Acute Leptospirosis in Hawaii. J. Clin. Microbiol.
40: 1464-1469
[Abstract]
[Full Text]
-
Flannery, B., Costa, D., Carvalho, F. P., Guerreiro, H., Matsunaga, J., Da Silva, E. D., Ferreira, A. G. P., Riley, L. W., Reis, M. G., Haake, D. A., Ko, A. I.
(2001). Evaluation of Recombinant Leptospira Antigen-Based Enzyme-Linked Immunosorbent Assays for the Serodiagnosis of Leptospirosis. J. Clin. Microbiol.
39: 3303-3310
[Abstract]
[Full Text]
-
Guerreiro, H., Croda, J., Flannery, B., Mazel, M., Matsunaga, J., Reis, M. G., Levett, P. N., Ko, A. I., Haake, D. A.
(2001). Leptospiral Proteins Recognized during the Humoral Immune Response to Leptospirosis in Humans. Infect. Immun.
69: 4958-4968
[Abstract]
[Full Text]
-
Levett, P. N.
(2001). Leptospirosis. Clin. Microbiol. Rev.
14: 296-326
[Abstract]
[Full Text]
-
Levett, P. N., Branch, S. L., Whittington, C. U., Edwards, C. N., Paxton, H.
(2001). Two Methods for Rapid Serological Diagnosis of Acute Leptospirosis. CVI
8: 349-351
[Abstract]
[Full Text]
-
Smits, H. L., Eapen, C. K., Sugathan, S., Kuriakose, M., Gasem, M. H., Yersin, C., Sasaki, D., Pujianto, B., Vestering, M., Abdoel, T. H., Gussenhoven, G. C.
(2001). Lateral-Flow Assay for Rapid Serodiagnosis of Human Leptospirosis. CVI
8: 166-169
[Abstract]
[Full Text]
-
Matsuo, K., Isogai, E., Araki, Y.
(2000). Utilization of Exocellular Mannan from Rhodotorula glutinis as an Immunoreactive Antigen in Diagnosis of Leptospirosis. J. Clin. Microbiol.
38: 3750-3754
[Abstract]
[Full Text]
-
Smits, H. L., van der Hoorn, M. A. W. G., Goris, M. G. A., Gussenhoven, G. C., Yersin, C., Sasaki, D. M., Terpstra, W. J., Hartskeerl, R. A.
(2000). Simple Latex Agglutination Assay for Rapid Serodiagnosis of Human Leptospirosis. J. Clin. Microbiol.
38: 1272-1275
[Abstract]
[Full Text]